Standard Lab Monitoring for Kisqali and Letrozole
Kisqali (ribociclib), a CDK4/6 inhibitor, combined with letrozole, an aromatase inhibitor, requires blood tests before starting treatment and regularly during therapy for HR+/HER2- advanced breast cancer. Monitoring focuses on Kisqali's risks like neutropenia, liver toxicity, and QT prolongation, with letrozole needing less frequent checks for bone health and lipids.
Complete Blood Count Checks Before and During Kisqali + Letrozole
Test complete blood count (CBC) with differential before the first dose, on days 15 and 29 of cycle 1, then at the start of each cycle (every 28 days). Continue monthly for cycles 2-6, then every 3 months if stable.
Neutrophil counts drop in 75% of patients (grade 3/4 in 62%), often within weeks, requiring dose interruptions or reductions.[1][2]
Liver Function Tests Timing and Frequency
Check liver enzymes (ALT, AST, bilirubin) before treatment starts, then every 2 weeks for the first 2 cycles, monthly for cycles 3-6, and every 3 months afterward. Elevated ALT/AST occurs in 10-13% at grade 3/4.[1][2]
ECG Monitoring for Heart Rhythm Risks
Perform ECG to measure QT interval before starting Kisqali, on day 14 of cycle 1, at cycle 2 start, and as clinically needed. Avoid if QTc >450 ms baseline; discontinue if >500 ms or >60 ms change. Electrolytes (potassium, calcium, magnesium, phosphorus) go with each ECG.[1][2]
Electrolytes and Other Routine Labs
Monitor potassium, calcium, magnesium, and phosphorus before treatment and with ECGs. No specific routine labs for letrozole alone, but check lipids and bone mineral density periodically in postmenopausal women due to estrogen suppression effects.[1][3]
What to Do If Labs Are Abnormal
- Neutrophils <1000/mm³: Interrupt Kisqali until recovery to ≥1000, reduce dose.
- ALT/AST >3x ULN: Pause until ≤2x ULN.
- QTc >500 ms: Stop Kisqali permanently.[1][2]
Letrozole rarely causes lab issues but may increase cholesterol; manage with statins if needed.[3]
[1]: Kisqali Prescribing Information, Novartis, accessed via FDA.gov
[2]: MONALEESA-2 Trial Data, New England Journal of Medicine (2016)
[3]: Letrozole Prescribing Information, Novartis, accessed via FDA.gov